A small number of stem cell therapies are FDA approved, but the vast majority of treatments marketed at clinics across the United States are not. The FDA has approved specific cord blood stem cell products for blood disorders, a cell-based cartilage repair product, donor pancreatic cells for type 1 diabetes, and several gene therapies that modify a patient’s own cells. The generic “stem cell therapy” advertised for joint pain, anti-aging, neurological conditions, or autoimmune diseases has no FDA approval.
That gap between what’s approved and what’s sold is enormous, and it’s the reason so many people end up searching this question in the first place.
What the FDA Has Actually Approved
The FDA maintains a public list of approved cellular and gene therapy products. The stem cell products on that list fall into a few narrow categories.
Cord blood products make up the largest group. Products like Allocord, Clevecord, Ducord, and Hemacord contain blood-forming stem cells collected from umbilical cord blood. They’re approved for transplant in patients with disorders affecting the blood or immune system, whether inherited, acquired, or caused by intensive cancer treatment. Think leukemia, lymphoma, sickle cell disease, and certain immune deficiencies. These transplants happen in hospital settings under the care of specialized medical teams, not at storefront clinics.
MACI is an approved product that uses your own cartilage cells. A surgeon takes a small sample of cartilage from your knee, the cells are grown in a lab and placed on a collagen membrane, then implanted to repair cartilage defects. It’s approved specifically for cartilage damage in the knee.
Lantidra uses donor pancreatic islet cells (the cells that produce insulin) and is approved for adults with type 1 diabetes who can’t control their blood sugar despite intensive management.
Casgevy and Lyfgenia are gene therapies approved for sickle cell disease. They work by collecting a patient’s own blood-forming stem cells, genetically modifying them in a lab, and infusing them back. These are one-time treatments performed at certified medical centers.
The list also includes several CAR-T cell therapies (like Kymriah, Breyanzi, Carvykti, and Abecma) for certain blood cancers. These collect a patient’s immune cells, engineer them to attack cancer, and return them to the body. While they involve cell manipulation, they’re distinct from what most people picture when they hear “stem cell therapy.”
What’s Not Approved
If a clinic is offering stem cell injections for back pain, knee arthritis, shoulder injuries, erectile dysfunction, Parkinson’s disease, autism, COPD, or “general rejuvenation,” none of those uses have FDA approval. The same goes for products derived from amniotic fluid, umbilical cord tissue, exosomes, or placental tissue that are marketed as regenerative medicine. These products have not been tested through the FDA’s approval process for safety or effectiveness.
This is not a technicality. The FDA draws a clear legal line based on two criteria: minimal manipulation and homologous use. A stem cell product can be sold without premarket FDA approval only if the cells haven’t been significantly altered from their natural state AND they’re being used to perform the same function in the recipient as they did in the donor. Fat-derived stem cells injected into a knee joint, for example, fail both tests. The fat tissue has been processed beyond minimal manipulation, and cushioning a joint is not the biological function fat performs in the donor.
Any product that crosses those lines is legally classified as both an unapproved drug and an unlicensed biological product, which means it requires full FDA review before it can be sold.
Why So Many Clinics Seem Legitimate
Hundreds of clinics in the U.S. market stem cell treatments that sound credible. Some reference clinical trials, display professional-looking credentials, or use medical terminology that implies government oversight. The International Society for Stem Cell Research has specifically warned that some companies register studies on ClinicalTrials.gov to create the impression of FDA approval, even though listing a trial on that database has nothing to do with being approved. A clinical trial means the treatment is being tested. It does not mean it works or is safe.
Some clinics also use language carefully designed to stay just vague enough. Phrases like “FDA-compliant facility” or “FDA-registered lab” refer to the physical space meeting basic safety standards for handling biological material. They say nothing about whether the actual treatment being injected into your body has been reviewed or approved.
Enforcement Is Ongoing
The FDA actively pursues clinics selling unapproved stem cell products. In a September 2025 warning letter, the agency cited a company called New Life Medical Services for selling umbilical cord-derived products and exosome products for uses that violated federal law. The FDA found the products failed both the minimal manipulation and homologous use standards, making them unapproved drugs and unlicensed biologics. The letter warned that failure to correct the violations could lead to seizure of products or an injunction shutting down operations.
This is a representative case, not an outlier. The FDA has issued dozens of similar warning letters and has sought court injunctions against clinics in Florida, California, Texas, and other states. Some of these actions came after patients suffered serious harm.
Risks of Unapproved Treatments
The FDA has documented cases of patients developing serious infections, tumors, and vision loss after receiving unapproved stem cell injections. Because these products haven’t gone through controlled testing, there’s no reliable data on how often complications occur or who is most at risk. Cells injected into the wrong environment can behave unpredictably. They may trigger immune reactions, migrate to unintended locations, or multiply in ways that cause new problems.
The financial risk is also significant. Unapproved stem cell treatments typically cost $5,000 to $25,000 or more per treatment, are almost never covered by insurance, and come with no guarantee of results. Patients often pay out of pocket for a product that has never been proven to do what the clinic claims.
How to Check a Treatment’s Status
The most reliable way to verify whether a specific stem cell product is FDA approved is to check the FDA’s list of approved cellular and gene therapy products, available on the FDA website. If the product or brand name isn’t on that list, it hasn’t been approved. You can also search for active clinical trials at ClinicalTrials.gov, but remember that an ongoing trial is not the same as an approved treatment. Legitimate clinical trials do not charge patients for the experimental therapy itself.
If a clinic tells you their treatment is “FDA approved” but the product doesn’t appear on the official list, that claim is false. If they say the treatment “doesn’t require FDA approval” because it uses your own cells, that claim depends entirely on how those cells are processed and used, and in most cases the processing involved at these clinics does trigger FDA jurisdiction.